<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166543">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929669</url>
  </required_header>
  <id_info>
    <org_study_id>809652</org_study_id>
    <nct_id>NCT00929669</nct_id>
  </id_info>
  <brief_title>Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas</brief_title>
  <acronym>LAR</acronym>
  <official_title>Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if administration of pasireotide LAR for one year
      to three patients with gonadotroph adenomas and elevated serum FSH concentrations will
      reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gonadotroph adenomas are the most common pituitary macroadenomas. Currently no medical
      treatment as been found that decreases the size of these adenomas, so surgery is the only
      treatment. The reason to think that pasireotide might affect gonadotroph adenomas is that
      pasireotide binds avidly to somatostatin subtype 5 receptors, and gonadotroph adenomas
      express these receptors. For this study, three subjects who have gonadotroph adenomas, as
      judged by a macroadenoma of the pituitary and elevated serum FSH concentration, will be
      treated with a long-acting form of pasireotide once a month for one year. The effect of
      pasireotide on the size of the adenoma will be determined by MRI, and FSH secretion will be
      judged by the serum concentration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to identify a third subject
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if pasireotide will decrease the size of gonadotroph adenomas as determined by MRI</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if pasireotide will decrease serum FSH concentration in patients who have gonadotroph adenomas.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Gonadotroph Adenomas</condition>
  <arm_group>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg IM once monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pasireotide LAR</intervention_name>
    <description>pasireotide LAR 80 mg IM once a month</description>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gonadotroph adenoma

        Exclusion Criteria:

          -  visual impairment attributable to the adenoma

          -  radiation therapy

          -  active gallbladder disease

          -  uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Snyder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 14, 2011</lastchanged_date>
  <firstreceived_date>June 23, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Peter J. Snyder, MD; Profesor of Medicine</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <keyword>pituitary tumor</keyword>
  <keyword>endocrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
